---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-011990"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:25:39.943917+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Collegium Q4 net rev $205.4M (+13% YoY); FY 2025 rev $780.6M (+24%); reaffirms 2026 guidance

## Summary
- Q4 GAAP diluted EPS $0.46 vs $0.36 YoY; adjusted diluted EPS $2.04 vs $1.77.
- Jornay PM Q4 net revenue $45.9M (+57%); full-year $148.9M (+48%).
- Pain portfolio FY 2025 net revenue $631.7M (+6%); Belbuca $221.7M (+5%).
- Full-year adjusted EBITDA $460.5M (+15%); cash & marketable securities $386.7M.
- Closed $980M credit facility in Dec; repurchased $25M shares in 2025.

## SEC filing metadata
- accession: 0001628280-26-011990
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000162828026011990/0001628280-26-011990-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000162828026011990/coll-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-011990
- JSON: https://secwatch.observer/filing/0001628280-26-011990.json
- Plain text: https://secwatch.observer/filing/0001628280-26-011990.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.